Alcohol & drugs · 4 first-stage items, then up to 3 per substance · 0-2+ per substance · McNeely 2016
TAPS Tool: Scoring, Cutoffs & Interpretation
Two-stage screen for tobacco, alcohol, prescription-medication misuse and other substance use.
Sex-specific alcohol wording
The heavy-drinking threshold is 5 or more drinks for males and 4 or more for females.
Stage 1 · TAPS-1
Past 12 months. Any answer other than "never" opens the second-stage questions for that substance.
01
In the PAST 12 MONTHS, how often have you used any tobacco product (for example, cigarettes, e-cigarettes, cigars, pipes, or smokeless tobacco)?
02
In the PAST 12 MONTHS, how often have you had 4 or more drinks containing alcohol in one day? One standard drink is about 1 small glass of wine (5 oz), 1 beer (12 oz), or 1 single shot of liquor.
03
In the PAST 12 MONTHS, how often have you used any drugs including marijuana, cocaine or crack, heroin, methamphetamine (crystal meth), hallucinogens, ecstasy/MDMA?
04
In the PAST 12 MONTHS, how often have you used any prescription medications just for the feeling, more than prescribed or that were not prescribed for you? Prescription medications that may be used this way include: opiate pain relievers (for example, OxyContin, Vicodin, Percocet, Methadone); medications for anxiety or sleeping (for example, Xanax, Ativan, Klonopin); medications for ADHD (for example, Adderall or Ritalin).
The TAPS (Tobacco, Alcohol, Prescription medication, and other Substance use) tool screens for unhealthy substance use across four classes in a single pass: tobacco, alcohol, prescription-medication misuse, and illicit drugs. It is a two-stage instrument. The first stage (TAPS-1) asks four frequency questions about use in the past 12 months; any answer other than 'never' triggers the second stage (TAPS-2), a brief assessment adapted from the ASSIST-Lite that asks two to three yes/no questions per endorsed substance class about use, dependence signs and concern from others over the past three months.\n\nThe result is a risk score for each substance class rather than a single global score. A score of 1 or more in a class indicates problem use; 2 or more indicates higher risk consistent with a possible substance use disorder. This per-substance structure lets a clinician see at a glance which class needs attention, rather than inferring it from a pooled total.
02 - Origin & purpose
Where it comes from.
TAPS was developed through the National Institute on Drug Abuse (NIDA) Clinical Trials Network to give primary care a single brief screener covering the substances clinicians most often need to ask about, replacing the need to stack separate instruments such as the AUDIT and DAST. The validation study, led by Jennifer McNeely and colleagues, was published in Annals of Internal Medicine in 2016 and compared TAPS against a modified WHO Composite International Diagnostic Interview in 2,000 adult primary-care patients.\n\nThe study validated both interviewer administration and self-administration on a tablet (myTAPS), which performed comparably - an unusual strength among substance-use screeners, most of which were validated in one mode only. A follow-up analysis published in the Journal of General Internal Medicine in 2017 validated the four-item TAPS-1 as a stand-alone first-stage screen. The tool is in the public domain and is distributed by NIDA.
03 - Scoring & cutoffs
How scoring works.
Each of the four substance classes is scored separately. TAPS-1 asks how often the person used each class in the past 12 months (never / less than monthly / monthly / weekly / daily or almost daily). Any use triggers the TAPS-2 questions for that class, which generate a risk score from 0 to 3 (0 to 4 for tobacco). In the validation study, a score of 1 or more identified problem use, and 2 or more identified higher-risk use consistent with a possible substance use disorder. There is no global total: interpret each substance class on its own, and treat any positive class as a prompt for a fuller conversation rather than a diagnosis.
04 - Validation evidence
How well it performs.
In the 2016 validation against a modified WHO CIDI reference standard in 2,000 adult primary-care patients, TAPS showed good to excellent discrimination (AUC ≥ 0.80) for tobacco, alcohol and cannabis. At the problem-use cutoff of 1 or more, sensitivity was 0.74 and specificity 0.79 for alcohol, and sensitivity 0.82 with specificity 0.93 for cannabis. Across illicit and prescription-medication classes, sensitivity at that cutoff ranged from 0.63 to 0.82 while specificity remained at or above 0.93 - high confidence in a positive screen, with more misses in rarer drug classes. Self-administration on a tablet performed comparably to interviewer administration.
Quick conversational screen covering alcohol and drugs; less graded detail.
WHO ASSIST
~8 items per substance
5-10 min
The fuller per-substance risk assessment TAPS-2 was condensed from; use when you need graded risk plus injection history.
NIDA Quick Screen
4 items
<1 min
The predecessor single-stage screen TAPS-1 was adapted from.
06 - When to use it
Right tool, wrong tool.
Reach for it when
-Universal screening at intake in primary care or psychiatry when you want all four substance classes covered in one brief pass
-Settings where patients can self-complete on a tablet or portal before the consultation
-Identifying which specific substance class needs follow-up, since each class gets its own risk score
-A public-domain tool that can be embedded in an EHR without licensing negotiation
Reach for something else when
-Monitoring severity or change over time - use AUDIT or DAST-10 for repeated severity measurement
-Adolescents - TAPS was validated in adults; use CRAFFT or S2BI instead
-Diagnosing a substance use disorder - a positive screen needs a clinical interview
-Quantifying alcohol consumption in units - TAPS asks frequency of heavy episodes, not weekly intake
07 - Confidence & precision
Reading the score with care.
TAPS is a categorical screener, not a dimensional severity measure, so a standard error of measurement and a minimal clinically important difference have not been established and would not be meaningful. Treat the per-class bands (0 none, 1 problem use, 2+ higher risk) as prompts with known error rates: specificity is high across drug classes, so positive screens are usually worth acting on, while sensitivity in the 0.63-0.82 range means a negative screen does not rule out use that the patient prefers not to disclose.
08 - Limitations
What it cannot tell you.
Sensitivity is lowest for prescription-medication misuse and less common drug classes, so negatives in those classes deserve the least weight. Like all self-report screeners it depends on disclosure, and performance was measured in research conditions with consented patients; routine-care disclosure may be lower.\n\nThe TAPS-2 window is the past three months, so episodic or seasonal use can be missed. Validation is in adults in US primary care; it has not been validated in adolescents, and cross-cultural validation is more limited than for the WHO ASSIST. It screens and stratifies risk but does not diagnose, and it does not quantify consumption.
[3]Wu LT, McNeely J, Subramaniam GA, et al. Design of the NIDA clinical trials network validation study of the TAPS tool. Contemp Clin Trials. 2016;50:90-97 ↩
See how Aisel removes friction where it costs most. A 20-minute walkthrough tailored to your clinic.
We value your privacy
We use cookies to analyse site usage and improve your experience. Analytics and embedded media (e.g. YouTube) only load if you accept. Read our cookie policy.